ストックスクリーナーアプリを入手
1.3615
3.41%
0.0415
前日終値:
$1.32
開ける：
$1.34
24時間の取引高:
160.12K
Relative Volume:
0.10
時価総額：
$38.20M
収益：
-
当期純損益:
$-64.47M
株価収益率:
-0.2201
EPS:
-6.1852
ネットキャッシュフロー:
$-52.33M
1週間 パフォーマンス:
+19.74%
1か月 パフォーマンス:
-13.06%
6か月 パフォーマンス:
-53.41%
1年 パフォーマンス:
-77.10%
1日の値動き範囲:
$1.32
$1.40
1週間の範囲:
$1.11
$1.4393
52週間の値動き範囲:
$1.11
$7.19
Jasper Therapeutics Inc Stock (JSPR) Company Profile
名前
Jasper Therapeutics Inc
セクター
電話
(650) 549-1400
住所
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Compare JSPR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
1.365 | 36.94M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.10 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.52 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.15 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.83 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.85 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | 開始されました | Rodman & Renshaw | Buy |
| 2025-07-08 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-09-09 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-08 | 開始されました | BTIG Research | Buy |
| 2024-06-27 | 開始されました | Stifel | Buy |
| 2024-05-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-03 | 開始されました | Evercore ISI | Outperform |
| 2024-03-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-18 | 開始されました | TD Cowen | Outperform |
| 2023-08-11 | 開始されました | CapitalOne | Overweight |
| 2022-02-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 開始されました | Credit Suisse | Outperform |
| 2021-10-21 | 開始されました | William Blair | Outperform |
| 2021-10-20 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-13 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Jasper Therapeutics Inc (JSPR) 最新ニュース
Jasper Therapeutics Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Stockholders to Inquire about Securities Investigation - accessnewswire.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Investors to Learn More About the Investigation - accessnewswire.com
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Stockholders to Learn More About the Investigation - accessnewswire.com
Jasper Therapeutics Announces Positive Updated Phase 1b/2a Data for Briquilimab in CSU - Dermatology Times
Jasper Therapeutics (NASDAQ:JSPR) Now Covered by Analysts at Rodman & Renshaw - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Reach Out - accessnewswire.com
Rodman & Renshaw initiates Jasper Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
RBC Capital Keeps Their Hold Rating on Jasper Therapeutics (JSPR) - The Globe and Mail
HOKA Trail Shoe Guide: Is Jasper Therapeutics Inc. Equity Warrant stock attractive for long term wealth buildingBest Sellers Snapshot & walk-ready comfort choices - Улправда
Jasper Therapeutics reports updated data from briquilimab studies - Yahoo Finance
Jasper Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Sahm
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria - Sahm
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Connect - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Jasper Therapeutics appoints Jeet Mahal as CEO in leadership transition By Investing.com - Investing.com Nigeria
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria - TipRanks
Jasper Therapeutics Reports Positive Data from Briquilimab Studies - TradingView — Track All Markets
Jasper Therapeutics stock rises after leadership changes By Investing.com - Investing.com Australia
Jasper Therapeutics stock rises after leadership changes - Investing.com India
Jasper Therapeutics appoints Jeet Mahal as CEO in leadership transition - Investing.com
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of ... - Bluefield Daily Telegraph
Jasper Therapeutics, Inc. Announces Executive Changes - marketscreener.com
What analysts say about Jasper Therapeutics Inc stockTop Performing Stocks & Low Risk Trading Alerts - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
2025-12-28 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out | NDAQ:JSPR | Press Release - Stockhouse
Jasper Therapeutics Earnings Notes - Trefis
Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN
Evercore ISI Remains a Buy on Jasper Therapeutics (JSPR) - The Globe and Mail
2025-12-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect | NDAQ:JSPR | Press Release - Stockhouse
Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 7.3% – Time to Sell? - Defense World
Penny Stocks To Watch NowDecember 2nd - MarketBeat
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper’s Stock Is In The Basement, But The Bet Is Binary - Finimize
Jasper Therapeutics Reports Positive Phase 1b Study Results - MSN
Jasper Therapeutics Inc (JSPR) 財務データ
収益
当期純利益
現金流量
EPS
Jasper Therapeutics Inc (JSPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lucas Svetlana | Director |
Sep 22 '25 |
Buy |
2.43 |
20,000 |
48,600 |
20,000 |
| MARTELL RON | President and CEO |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
74,118 |
| Shizuru Judith Anne | Director |
Sep 22 '25 |
Buy |
2.43 |
41,000 |
99,630 |
156,901 |
0.81%
0.77%
大文字化:
|
ボリューム (24 時間):